# The Aberdeen Children of the 1950s study

https://neurodegenerationresearch.eu/survey/the-aberdeen-children-of-the-1950s-study/

**Title of the cohort**

The Aberdeen Children of the 1950s study

**Acronym for cohort**

ACONF

**Name of Principal Investigator**

| | |
|---|---|
| Title | Professor |
| First name | Sally |
| Last name | Macintyre |

**Address of institution where award is held**

| | |
|---|---|
| Institution | MRC Social and Public Health Sciences Unit |
| Street Address | 4 Lilybanks Gardens |
| City | Glasgow |
| Postcode | G12 8RZ |

**Country**

United Kingdom

**Website**

http://www.abdn.ac.uk/aconf/

**Contact email**

h.clark@abdn.ac.uk

**Funding source**

The MRC and the University of Aberdeen

**1. The cohort includes, or expects to include, incidence of the following conditions**

- Neurodegenerative disease in general

**When studies on the above condition(s) are expected to become possible**

2016 – 2025

**2a. Stated aim of the cohort**

The Children of the 1950s study is a population-based resource for the study of biological and social influences on health across the life-course and between generations.

**2b. Features distinguishing this cohort from other population cohorts**

5 to 12

**3a. i) Number of publications that involve use of cohort to date**
0
**3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)**
**3b. Publication list/link to where data or publications are accessible (if available)**

http://www.abdn.ac.uk/aconf/frameset.html

**3c. Information (i.e. research findings) expected to be gained from the population cohort**
**4a. Study criteria: age range of participants at recruitment**
Age in years from: 5 to 12
To ('until death' if applicable): until death
**4b. Study criteria: inclusion criteria**

All children born 1950 to 1956 in Aberdeen, Scotland who took part in a survey in that city when in primary school in 1962

**4c. Study criteria: exclusion criteria**

None

**5. Size of the cohort (i.e. number of participants enrolled)**

10,001 – 15,000 participants

**6a. Measures used to characterise participants**

Participants are characterised by birth weight, childhood height and weight, tests of cognition and behavioural disorder, and a range of multi-level socio-economic indicators.

**6b. Additional measures for participants with a clinical disorder**

No

**6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

No

**7. Study design**

- Longitudinal

**8. Cases matched by**

- Age

**9a. Does the study include a specialised subset of control participants**

No

**9b. If yes, description of specialised subset of control participants**
**10a. i) Data collection start date**

01-12-1962

**10a. ii) Data collection end date**
**10a iii) Data collection for this study is**

- Data collection ongoing

**10b. Plans to continue the cohort study beyond the current projected end date**
**11. Data collected**

- Through links to medical records
- Through links to other records or registers (such as dental records, police records etc). Please specify
- General Register's Office deaths and events notifications

**12. System in place to enable re-contact with patients for future studies**

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

**13a. Format and availability of data stored in a database**
**Language used:**

English

**13b. Format and availability of data held as individual records**

| | Yes/No | % available |
|---|---|---|
| Data summarised in database | | |
| Database is web-based | | |
| Database on spreadsheet | | |
| Database is on paper | yes | 100 |
| Other (specify) | | |

**Language used:**

English

**14a. Are data available to other groups**

Yes

**14b. Access policy/mechanisms for access if data are available to other groups**

- Access Committee mechanism
- International access
- Resource has own ethics approval so usually no need for separate external ethics approval

**15. Data sharing policy specified as a condition of use**

No policy exists

**16a. Are tissues/samples/DNA available to other groups**

No

**16b. i) Description of available tissues/samples/DNA**
**16b. ii) Form available tissues/samples/DNA are supplied in**
**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**
**17. Is information on biological characteristics available to other groups**

- No